Key result
Plasma ANGPTL6 levels were associated with an increased risk of type 2 diabetes (OR 1.04) and obesity (OR 1.03), whereas MPO levels were upregulated in obesity independent of diabetes status.
Why the study?
This study evaluated plasma MPO and ANGPTL6 levels in obese and diabetic individuals and assessed MPO associations with biochemical markers of obesity.
Population
238 participants, including 137 control and 101 type 2 diabetes patients
Comparison
Obese vs non-obese participants and type 2 diabetes vs control participants
Authors
Loading...
ANGPTL6 and MPO associations with metabolic traits are hypothesis-generating; prospective studies needed before any biomarker or therapeutic role.
Cross-Sectional (n=238)
No
Odds Ratio: 1.04 (95% CI 1.01–1.08)
ANGPTL6 is elevated in type 2 diabetes potentially as a modulatory response, whereas MPO is elevated in obesity independent of diabetes status, suggesting distinct roles in metabolic disease.
Qaddoumi et al. (2020) conducted a cross-sectional in Obesity and Type 2 Diabetes (n=238). Plasma ANGPTL6 levels vs. Baseline/lower levels was evaluated on Risk of Type 2 Diabetes (OR 1.04, 95% CI 1.01-1.08). Plasma ANGPTL6 levels were associated with an increased risk of type 2 diabetes (OR 1.04) and obesity (OR 1.03), whereas MPO levels were upregulated in obesity independent of diabetes status.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: